Skip to main content

Table 1 Demographical and clinical characteristics of 121 patients with systemic sclerosis

From: Cross-sectional study of soluble selectins, fractions of circulating microparticles and their relationship to lung and skin involvement in systemic sclerosis

Patients

All

lcSSc

dcSSc

Gender, males/females, n

19/102

3/76

16/26

Age, mean ± SD (range) years

57 ± 12 (22-79)

59 ± 11

55 ± 12

Disease duration, mean ± SD (range) years

12 ± 9 (0-53)

12 ± 9

11 ± 9

Cutaneous Involvement

   

ᅟModified Rodnan skin score, mean ± SD

11 ± 9

7 ± 3

20 ± 9

ᅟCutaneous ulcers, all, n

68

44

24

ᅟCutaneous ulcers, present, n

23

10

13

ᅟCutaneous ulcers, past, n

45

34

11

ᅟCalcinosis, n (N)*

43 (107)

30

13

Pulmonary and Cardiac involvement

   

ᅟDLCO, mean ± SD % predicted (N)*

64.6 ± 19.9 (118)

64.2 ± 18.5 (77)

66.3 ± 20.3 (41)

ᅟPatients with DLCO < 80 (%)

75 %

79 %

74 %

ᅟFVC, mean ± SD % predicted (N)*

95.7 ± 21.1 (118)

99.3 ± 20.1 (77)

89.1 ± 21.7 (41)**

ᅟPatients with FVC < 80 (%)

22 %

20 %

27 %

ᅟRadiographically confirmed lung fibrosis, n

21

14

7

ᅟElevated SPAP by echocardiography, n (N)*

10 (115)

6

4

Serology

   

ᅟAnti-nuclear antibodies, n

116

74

42

ᅟAnti-Scl-70 antibodies, n

15

3

12

ᅟAnti-centromere antibodies, n

49

41

8

ᅟPeripheral blood

   

ᅟLeukocytes total, mean ± SD (x 109/L)

7.2 ± 2.2

7.4 ± 2.5

7.1 ± 2.3

ᅟNeutrophils, mean ± SD, (x 109/L)

4.6 ± 1.8

4.7 ± 2.0

4.4 ± 1.6

ᅟPlatelets, mean ± SD, (x 109/L)

275 ± 86

265 ± 86

268 ± 72

Others

   

ᅟDMARDS, n

8

4

4

ᅟCurrent or previous smokers, n

83

57

26

ᅟArterial hypertension, n

30

18

12

  1. dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; anti-Scl-70: anti-topoisomerase-1; DMARDS: disease modifying anti rheumatic drugs; arterial hypertension: blood pressure above 140/90 mmHg at study inclusion; DLCO: carbon monoxide diffusing capacity in percent of predicted values; FVC: vital capacity in percent of predicted values. n: number of subjects with feature. N: total number of subjects in the group. *: reduced number of patients due to lack of information. **, p < 0.01